Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $187,773 | 38 | 67.1% |
| Travel and Lodging | $40,668 | 69 | 14.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $30,562 | 5 | 10.9% |
| Unspecified | $13,521 | 2 | 4.8% |
| Food and Beverage | $5,153 | 81 | 1.8% |
| Honoraria | $2,055 | 1 | 0.7% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $59,832 | 71 | $0 (2024) |
| Mallinckrodt LLC | $47,824 | 15 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $42,417 | 23 | $0 (2023) |
| Kite Pharma, Inc. | $31,873 | 20 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $17,310 | 3 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $14,688 | 8 | $0 (2024) |
| Genentech, Inc. | $14,040 | 2 | $0 (2021) |
| Janssen Scientific Affairs, LLC | $9,360 | 1 | $0 (2021) |
| GENZYME CORPORATION | $8,256 | 7 | $0 (2017) |
| Gilead Sciences, Inc. | $6,857 | 7 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,133 | 27 | Incyte Corporation ($19,414) |
| 2023 | $30,544 | 33 | Incyte Corporation ($15,785) |
| 2022 | $12,015 | 12 | Kite Pharma, Inc. ($9,349) |
| 2021 | $47,160 | 9 | Genentech, Inc. ($14,040) |
| 2020 | $16,213 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($5,610) |
| 2019 | $33,077 | 41 | Incyte Corporation ($14,539) |
| 2018 | $67,226 | 36 | Novartis Pharmaceuticals Corporation ($27,128) |
| 2017 | $41,362 | 31 | Mallinckrodt LLC ($22,694) |
All Payment Transactions
196 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Consulting Fee | Cash or cash equivalent | $8,726.00 | General |
| 09/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $996.66 | General |
| 09/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $534.14 | General |
| 09/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Travel and Lodging | In-kind items and services | $265.07 | General |
| 09/05/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $91.86 | General |
| 08/08/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $7,535.00 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $605.94 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $326.84 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $216.25 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $76.00 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $59.48 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $53.24 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $29.87 | General |
| 08/08/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $18.76 | General |
| 08/08/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $4.38 | General |
| 08/07/2024 | Incyte Corporation | — | Travel and Lodging | Cash or cash equivalent | $219.00 | General |
| 08/07/2024 | Incyte Corporation | — | Food and Beverage | Cash or cash equivalent | $48.85 | General |
| 07/11/2024 | Incyte Corporation | JAKAFI (Drug) | Consulting Fee | Cash or cash equivalent | $7,018.75 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $2,384.05 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $342.84 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $157.02 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $46.19 | General |
| Category: Hematology/Oncology | ||||||
| 05/17/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Hematology/Oncology | ||||||
| 05/16/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $208.00 | General |
| Category: Hematology/Oncology | ||||||
| 05/16/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $47.35 | General |
| Category: Hematology/Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RELAPSED OR REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (NHL) | Takeda Pharmaceuticals U.S.A., Inc. | $8,450 | 1 |
| Phase I Dose Escalation Trial of RO7082859 in patients with R R NHL | F. Hoffmann-La Roche AG | $5,071 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 18 | 101 | $40,299 | $9,090 |
| 2020 | 1 | 14 | 117 | $46,683 | $10,787 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 101 | $40,299 | $9,090 | 22.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 117 | $46,683 | $10,787 | 23.1% |
About Dr. Krishna Komanduri, M.D
Dr. Krishna Komanduri, M.D is a Hematology & Oncology healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1598850265.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Krishna Komanduri, M.D has received a total of $279,731 in payments from pharmaceutical and medical device companies, with $32,133 received in 2024. These payments were reported across 196 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($187,773).
As a Medicare-enrolled provider, Komanduri has provided services to 32 Medicare beneficiaries, totaling 218 services with total Medicare billing of $19,877. Data is available for 2 years (2020–2021), covering 2 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Miami, FL
- Active Since 10/04/2006
- Last Updated 02/27/2013
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1598850265
Products in Payments
- Yescarta (Drug) $25,602
- UVADEX METHOXSALEN STERILE SOLUTION (Drug) $25,131
- KYMRIAH (Biological) $24,660
- UVADEX (METHOXSALEN) STERILE SOLUTION (Drug) $22,694
- RYDAPT (Drug) $16,847
- JAKAFI (Drug) $10,255
- MOZOBIL (Drug) $8,256
- REZUROCK (Drug) $4,074
- Rezlidhia (Drug) $2,245
- CARVYKTI (Drug) $2,030
- TSPOT TB TEST (Device) $458.25
- KEVEYIS (Drug) $92.32
- IMBRUVICA (Drug) $26.08
- SOLIRIS (Drug) $24.74
- Revlimid (Drug) $22.06
- BESPONSA (Biological) $15.74
- Imbruvica (Drug) $15.46
- MEKINIST (Drug) $14.85
- KYMRIAH (Drug) $12.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Miami
Dr. Steven Fein, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Carl Landgren, Md, MD
Hematology & Oncology — Payments: $751,068
Dr. Fernando De Zarraga, M.d, M.D
Hematology & Oncology — Payments: $649,574
Mr. Neil Nagovski, Md, MD
Hematology & Oncology — Payments: $533,284
Srikanth Nagalla, Md, MD
Hematology & Oncology — Payments: $510,589
Raja Mudad, Md, MD
Hematology & Oncology — Payments: $442,163